Vitrafy Life Sciences Ltd. · ASX:VFY
Vitrafy Life Sciences — Bell Potter Healthcare Conference 2025
13 slides from Vitrafy Life Sciences's conference presentation, Nov 19, 2025
Slide 1: ASX Announcement: Bell Potter Healthcare Conference Presentation
ASX ANNOUNCEMENT 19 November 2025 Bell Potter Healthcare Conference Presentation Vitrafy Life Sciences Limited (ASX: VFY), (Vitrafy or Company) will deliver the attached presentation at the Bell Potter Healthcare Conference on Thursday, 20 November 2025. ### ENDS ### For personal use only This annou
Slide 2: Bell Potter Healthcare Conference
For personal use only Bell Potter Healthcare Conference November 2025 Vitrafy Life Sciences Limited (ASX: VFY) ACN 622 720 254 vitrafy.com 1
Slide 3: Important Notice and Disclaimer
Legal Notice Important Notice and Disclaimer This presentation contains summary information about Vitrafy Life Sciences Limited (ACN 622 720 254) and its related bodies corporate (together “Vitrafy” or “the Company”) and Vitrafy’s activities as at the date of this presentation. It is information giv
Slide 4: Introduction: Preserving Life
Introduction Preserving Life Vitrafy is an Australian founded, For personal use only USA focused cryopreservation technology company that is on a mission to become the global leader in cryopreservation and set new industry quality standards for cryopreserved materials, preserving life. 3
Slide 5: Company Overview
Company Overview For personal use only Disruptive Technology Superior Quality Outcomes Substantial Market Opportunity Novel cryopreservation devices, Cell survival rates up to Multiple applications across and an integrated software ~100% improvements animal and human health platform to retain the qu
Slide 6: Cryopreservation Problem
Cryopreservation Problem Cryopreservation Legacy cryopreservation workflows compound variability, leading to low For personal use only preserves biological materials by cooling recovery and >50% post-thaw quality loss . 1 samples to very low temperatures for future Commercial Applications Market Pro
Slide 7: The Vitrafy Solution: A new standard of quality
The Vitrafy Solution: A new standard of quality Vitrafy’s cryopreservation technology integrates software and hardware solutions to deliver quality outcomes for Human and Animal Health which can materially impact the economics of healthcare. For personal use only Enterprise Intelligent Workflow Plat
Slide 8: The Vitrafy Advantage
The Vitrafy Advantage Vitrafy’s cryopreservation technology has the ability to successfully cryopreserve and retain the quality of biological materials, such as life-saving haemorrhage control products, to a level comparable to fresh samples, without the use of toxic cryoprotectants. For personal us
Slide 9: Priority Go To Market Applications
Priority Go To Market Applications Vitrafy’s For personal use only cryopreservation technology has widespread applications across a variety of biological materials. Animal Reproduction Blood & Blood Products Cell & Gene Therapies Why Global Scale Critical & growing need Rapid growth Commercial Ready
Slide 10: Platelet Case Study: Prevent – Prepare – Readiness - Respond
Platelet Case Study: Prevent – Prepare – Readiness - Respond Haemorrhage is by far the leading cause of preventable death in combat: by many estimates, blood loss is responsible for up to 90% of injury fatalities. For personal use only NEW OPPORTUNITIES WITH IMMEDAITE MARKET NEED VITRAFY Vitrafy’s c
Slide 11: Platelet Case Study: Game Changing Opportunity
Platelet Case Study: Game Changing Opportunity The phase 1 study exceeded all regulatory and industry standards. For personal use only Problem Vitrafy solution Current industry standards Game Changing Outcomes 25 5 2 >2 >50% mins >89% mins days years Wash step No Wash Post-thaw platelet Post-thaw pl
Slide 12: FY26 Roadmap
FY26 Roadmap Significant Milestones ahead Well capitalised for growth For personal use only Market development Technology development $25.8m Total cash and liquid assets • Global scaling of Animal reproduction • Freezing device 1st release • All USA priority application markets unlocks • Freezing de
Slide 13: Thank you
Preserving Life For personal use only Thankyou November 2025 Vitrafy Life Sciences Limited (ASX: VFY) ACN 622 720 254 vitrafy.com 12
Vitrafy Life Sciences — Bell Potter Healthcare Conference 2025 on 6ix